Can You Commit to Prescribing a Specific Medication, Like Wegovy®?

Why No Provider Can Pre-Commit to a Specific GLP-1 Brand

A clinician who promises you Wegovy® before reading your chart is not practicing medicine. They are practicing marketing. The U.S. Drug Enforcement Administration and state medical boards require that a valid patient-physician relationship, including a documented clinical evaluation, precede any prescription. The FDA's labeling for semaglutide 2.4 mg (Wegovy®) itself lists contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, that a prescriber must actively screen for before writing the script.

The Legal Standard for Telehealth Prescribing

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 established that a practitioner must conduct at least one in-person medical evaluation, or qualify under a DEA telemedicine exception, before prescribing controlled substances. While GLP-1 agonists are not DEA-scheduled, every state medical board applies a parallel duty-of-care standard: prescriptions must follow from a legitimate clinical encounter. The Federation of State Medical Boards' 2020 telemedicine policy states that "the standard of care for telehealth services should be consistent with in-person care."

What a Real Clinical Evaluation Covers

Before any GLP-1 prescription is appropriate, your provider needs to assess:

• Current BMI and weight trajectory over the past 12 months
• Presence of qualifying comorbidities: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
• Personal and family history of thyroid tumors or MEN2
• Kidney function (eGFR), because dose adjustments may apply
• History of pancreatitis, gallbladder disease, or gastroparesis
• Current medications that interact with GLP-1 agents, particularly insulin secretagogues that raise hypoglycemia risk
• Mental health history, since some patients report mood changes on GLP-1 therapy

Skipping any of these items to hand you a brand name faster is a patient-safety failure, not a service upgrade.

How Wegovy® Actually Works, and What the Evidence Shows

Semaglutide 2.4 mg (Wegovy®) is a glucagon-like peptide-1 receptor agonist administered as a once-weekly subcutaneous injection. It mimics endogenous GLP-1, slowing gastric emptying, suppressing appetite at the hypothalamic level, and improving insulin secretion in a glucose-dependent manner. The FDA approved it in June 2021 specifically for chronic weight management, making it distinct from the 1.0 mg semaglutide formulation (Ozempic®) approved for type 2 diabetes.

STEP Trial Data: The Numbers That Matter

The STEP-1 trial (N=1,961 adults without diabetes) showed semaglutide 2.4 mg produced a mean 14.9% reduction in body weight at 68 weeks compared to 2.4% in the placebo group (P<0.001). [1] That translates to roughly 33.7 lbs lost in a 225-lb participant.

The STEP-2 trial (N=1,210 adults with type 2 diabetes) found a 9.6% mean weight reduction at 68 weeks, meaningfully lower than in non-diabetic participants, which influences which agent a clinician might choose for a patient who also needs glycemic control. [2]

The SELECT cardiovascular outcomes trial (N=17,604 adults with overweight or obesity and established cardiovascular disease, no diabetes) found that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% versus placebo over a mean follow-up of 33.3 months (HR 0.80; 95% CI 0.72 to 0.90; P<0.001). [3] The FDA approved a cardiovascular risk-reduction indication for Wegovy® in March 2024 based on this trial, making cardiovascular history a genuine clinical factor, not just a checkbox.

Dose Titration and Why It Takes Months

Wegovy® is started at 0.25 mg weekly and titrated upward every 4 weeks through 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. The full 68-week STEP-1 protocol required 16 weeks just to reach the maintenance dose. Patients who expect the maximum dose on week one misunderstand the pharmacology. Rushing titration significantly raises the rate of nausea, vomiting, and treatment discontinuation.

Wegovy® vs. Other GLP-1 and GIP/GLP-1 Agents: How Clinicians Choose

Your clinician is not withholding Wegovy® to be difficult. They are selecting from a list of agents that have meaningfully different efficacy profiles, approval statuses, insurance coverage rules, and side-effect burdens.

Tirzepatide (Zepbound® / Mounjaro®): The Dual-Agonist Option

Tirzepatide activates both GIP and GLP-1 receptors. The SURMOUNT-1 trial (N=2,539) found that tirzepatide 15 mg produced a mean weight loss of 20.9% at 72 weeks versus 3.1% placebo. [4] That is a larger effect size than any semaglutide dose studied in STEP-1. For a patient without type 2 diabetes who is tolerating injections and has no contraindication to tirzepatide, Zepbound® may be the better clinical choice, even if they came in asking for Wegovy®.

Liraglutide (Saxenda®): Still Appropriate in Specific Scenarios

Liraglutide 3.0 mg (Saxenda®) was FDA-approved for chronic weight management in 2014. The SCALE Obesity and Prediabetes trial (N=3,731) showed a mean 8.4% weight loss at 56 weeks versus 2.8% placebo. [5] The effect size is smaller than semaglutide or tirzepatide, but liraglutide is dosed daily and has a longer safety track record. Patients who have experienced unusual psychiatric side effects on weekly GLP-1 agents sometimes tolerate daily dosing better, and some insurance formularies cover Saxenda® when they do not cover Wegovy®.

Oral Semaglutide (Rybelsus®): The Injection-Free Route

Rybelsus® (semaglutide 7 mg and 14 mg oral tablets) is FDA-approved for type 2 diabetes, not for weight management. A clinician who prescribes it off-label for weight loss in a patient without diabetes is making a justifiable clinical judgment in some cases, but they are not substituting it directly for Wegovy® because the weight-loss data at the oral doses are less strong.

Compounded Semaglutide: The Nuanced Middle Ground

During the FDA shortage period for Wegovy® and Ozempic®, compounded semaglutide from 503A and 503B pharmacies became widely prescribed. The FDA removed semaglutide from the shortage list in early 2025. Once a drug is no longer on the shortage list, federal law generally prohibits 503A compounding pharmacies from compounding copies of it, though 503B outsourcing facilities operate under different rules. Any telehealth platform still offering "compounded semaglutide" after the shortage resolution should be providing a clear regulatory explanation. HealthRX clinicians review the current shortage status at every prescribing decision and document the rationale.

The HealthRX Prescribing Decision Framework for GLP-1 Agents

Rather than pre-committing to a brand, HealthRX clinicians apply a structured decision process. The framework below represents the clinical logic used internally and is shared here to help patients understand what drives the recommendation they receive.

Step 1. Confirm eligibility. FDA labeling for Wegovy® requires a BMI of 30 or greater, OR a BMI of 27 or greater with at least one weight-related comorbidity. A patient with a BMI of 25 and no comorbidities does not meet the labeled indication, and prescribing outside that indication requires documented clinical justification.

Step 2. Assess cardiovascular history. Patients with established atherosclerotic cardiovascular disease now have a specific FDA-approved indication for semaglutide 2.4 mg based on SELECT. That indication may make Wegovy® the preferred choice even if tirzepatide might otherwise produce greater weight loss.

Step 3. Review diabetes status. A patient with type 2 diabetes may be better served by Ozempic® (semaglutide 1.0 mg) or Mounjaro® (tirzepatide), both of which carry a diabetes indication and have A1c-reduction data that pure weight-management agents lack.

Step 4. Check insurance and cost tolerance. At a list price near $1,350 per month, Wegovy® is unaffordable without coverage for most patients. If a patient's plan covers Zepbound® but not Wegovy®, prescribing the non-covered agent is not in their interest, regardless of which brand they requested.

Step 5. Screen for contraindications. Thyroid cancer history or family history of MEN2: both agents are contraindicated. History of pancreatitis: clinical judgment required. Active eating disorder: GLP-1 therapy needs psychiatric co-management.

Step 6. Discuss injection vs. Oral preference. Some patients are needle-phobic. Some have compliance patterns that suit weekly injections better than daily ones. This is a genuine clinical variable, not a preference to be overridden.

What Happens When Insurance Does Not Cover Wegovy®

Insurance coverage for GLP-1 agents for weight management remains inconsistent. A 2023 analysis published in JAMA Health Forum found that only about 38% of commercial plans covered anti-obesity medications in 2022, and coverage criteria varied dramatically by state and employer. [6]

Manufacturer Savings Programs

Novo Nordisk offers the Wegovy® savings card for commercially insured patients, which may reduce out-of-pocket costs to as low as $0 for eligible patients in qualifying months. Eli Lilly has a comparable program for Zepbound®. These programs do not apply to Medicare, Medicaid, or uninsured patients.

When Medicaid Covers GLP-1 Agents

As of 2024, only a minority of state Medicaid programs cover GLP-1 agents for obesity without a diabetes diagnosis. Some state programs cover Victoza® (liraglutide 1.8 mg) for diabetes while not covering Saxenda® (liraglutide 3.0 mg) for weight loss, even though the molecule is identical. Your HealthRX clinician can document medical necessity language that supports a prior authorization appeal.

Prior Authorization: The Process and Timeline

Most commercial plans require a prior authorization for GLP-1 agents. Required documentation typically includes BMI records, comorbidity documentation, and evidence of a prior supervised weight-loss attempt of at least 6 months. HealthRX clinical staff submit prior authorization requests and handle appeals. Approval timelines range from 3 to 30 days depending on the plan.

What Patients Should Bring to Their First Appointment

Arriving prepared shortens the time between evaluation and prescription. Bring or have ready:

• Your current weight and a weight history going back 12 months if available
• A list of all current medications, including supplements and over-the-counter drugs
• Recent lab work: fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel (within 12 months)
• Your insurance card and the name of your pharmacy benefits manager (not always the same as your health insurer)
• A clear statement of your weight goal and any prior weight-loss attempts, including programs, medications, and duration

If you have a prior Wegovy® or GLP-1 prescription from another provider, bring that documentation. A clinician reviewing a patient who already tolerated 1.0 mg semaglutide for 6 months without adverse effects has far more to work with than one starting from scratch.

Common Misconceptions About GLP-1 Prescribing

"If I ask for Wegovy®, I should get Wegovy®"

Patients have a right to express preferences, and clinicians should take those preferences seriously. But the FDA, not the patient, defines the labeled indication. And the physician, not the patient, bears legal and ethical responsibility for the prescription. A provider who lets brand preference override clinical judgment is not serving the patient.

"Telehealth platforms that guarantee Wegovy® are better"

A platform that advertises guaranteed Wegovy® prescriptions before evaluation is advertising something a licensed clinician cannot ethically provide. The American Medical Association's Code of Medical Ethics states that physicians must base treatment decisions on sound medical principles rather than patient or commercial pressure. [7] A platform making that guarantee is either misleading prospective patients or has built a system that bypasses appropriate medical review.

"Compounded semaglutide is the same as Wegovy®"

Compounded semaglutide uses the same active molecule but is not FDA-approved, has not undergone the same manufacturing quality controls as Novo Nordisk's product, and does not carry the same labeling or post-market surveillance. The FDA issued a safety communication in 2024 noting reports of dosing errors, including hospitalizations, associated with compounded semaglutide products. [8] Some compounded products also add cyanocobalamin (B12) or other ingredients not present in the branded formulation, without clinical evidence supporting those additions.

"If I lose weight fast at the start, I should skip titration"

Early weight loss on a sub-therapeutic dose (0.25 mg or 0.5 mg) reflects water loss and caloric restriction, not full GLP-1 receptor engagement. Skipping to 2.4 mg early does not increase efficacy proportionally and substantially raises the risk of severe nausea, vomiting, and gastroparesis-like symptoms.

The Role of Lifestyle Support Alongside GLP-1 Therapy

The FDA's approval of Wegovy® was for use "as an adjunct to a reduced-calorie diet and increased physical activity." That language is not decorative. The STEP-1 trial provided all participants with lifestyle counseling. Participants who lost the most weight combined medication adherence with behavioral changes.

The American Gastroenterological Association's 2022 Clinical Practice Update on GLP-1 use for obesity notes that "pharmacotherapy should be combined with behavioral interventions to maximize and maintain weight loss." [9] HealthRX includes structured nutrition and activity coaching as part of the GLP-1 program because the clinical evidence supports it, not as a way to justify a higher program price.

Stopping GLP-1 Therapy: What the Data Show

The STEP-4 trial (N=803) enrolled patients who had already lost weight on semaglutide 2.4 mg for 20 weeks, then randomized them to continue semaglutide or switch to placebo for another 48 weeks. The placebo group regained an average of 6.9 percentage points of body weight; the semaglutide group continued to lose 7.9 percentage points. [10] Weight regain after stopping GLP-1 therapy is not a personal failure. It reflects the chronic, neurohormonal nature of obesity. This is why HealthRX clinicians discuss long-term treatment planning from the first visit, not after a patient has already stopped.